The trajectory of Sildenafil presents a nuanced case for observers in the medicinal sector. While initially a blockbuster success, producing vast sums, the intellectual property end and the subsequent arrival of off-brand competitors have significantly affected income. This raises questions about the long-term viability of similar medication projec